Last reviewed: June 17, 2026
Last updated: June 17, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
Semaglutide, the active compound in Ozempic, has transformed weight management for millions, yet specific medical conditions and histories make it unsuitable for certain individuals. The FDA has identified absolute contraindications that exclude patients entirely, while relative contraindications require careful evaluation and clinical monitoring. PlexusDx helps eligible patients access compounded semaglutide injections starting at $149/month, but only after comprehensive screening ensures safety.
Absolute Contraindications: When Semaglutide Is Not An Option
Absolute contraindications are medical conditions that make semaglutide therapy dangerous regardless of potential benefits. Patients with personal or family history of medullary thyroid carcinoma (MTC) cannot use GLP-1 medications, as animal studies showed the compounds increase C-cell thyroid tumors in rodent models. Similarly, individuals with multiple endocrine neoplasia type 2 (MEN2), a hereditary condition affecting several glands, must avoid semaglutide entirely due to substantially elevated thyroid cancer risk.
Women who are pregnant or planning pregnancy within the next few months should discontinue semaglutide before conception. The medication remains in the body for several weeks after the final injection, and while human pregnancy studies are limited, animal data suggests potential effects on fetal development. Breastfeeding mothers should also avoid semaglutide, as the compound's presence in breast milk has not been thoroughly studied in infants.
Relative Contraindications: Conditions Requiring Medical Evaluation
Relative contraindications do not automatically disqualify patients but demand careful clinical assessment and informed consent. Individuals with a history of diabetic retinopathy—eye damage from diabetes—may experience temporary vision changes when blood sugar drops rapidly on semaglutide, though this typically resolves within weeks. Patients with severe kidney disease or on dialysis require dose adjustments and close monitoring, as GLP-1 medications can affect fluid balance and kidney function. Those with acute pancreatitis or chronic pancreatitis history face increased risk of inflammation recurrence, though the absolute risk remains low.
Patients taking insulin or certain diabetes medications face higher hypoglycemia risk when starting semaglutide, since the compound reduces blood sugar through multiple pathways simultaneously. Individuals with gallbladder disease or history of gallstones should be monitored, as rapid weight loss can precipitate gallstone formation. Those with inflammatory bowel disease, including Crohn's disease or ulcerative colitis, may experience symptom exacerbation, though evidence remains mixed regarding causation versus coincidence.
Personal Risk Factors That May Limit Eligibility
Beyond formal contraindications, personal medical history shapes semaglutide suitability. Individuals with suicidal ideation or ongoing psychiatric instability require stabilization before starting GLP-1 therapy, as nausea and appetite suppression can complicate mental health management. Those with severe gastrointestinal conditions—such as gastroparesis or severe GERD—may face worsening symptoms, since semaglutide slows gastric emptying. Patients with uncontrolled hypertension should achieve blood pressure control first, as rapid weight loss on medication can cause temporary fluctuations.
A history of anaphylaxis or severe allergic reactions to semaglutide or any GLP-1 medication excludes patients from therapy. Those with untreated or poorly controlled thyroid disease need endocrinology evaluation before starting, since semaglutide's effects on metabolism interact with thyroid function. Patients younger than 18 generally lack sufficient safety data, though some pediatric protocols are emerging under specialist supervision.
How PlexusDx Screens for Safety and Personalized Alternatives
PlexusDx requires a comprehensive health questionnaire and provider consultation before dispensing any GLP-1 medication from its licensed 503A compounding pharmacies. This screening process identifies absolute contraindications, evaluates relative ones, and determines whether dose adjustments or additional monitoring are necessary. Patients with borderline suitability receive detailed informed consent documents explaining specific risks tied to their medical profile. The entire process protects patient safety while expanding access to those who qualify.
For individuals with relative contraindications, PlexusDx offers alternatives beyond standard semaglutide injection. The Precision Peptide Genetic Test ($99 add-on after first month) maps 14 metabolic pathways and 49 peptide mechanisms to identify whether alternative compounds like tirzepatide injection or oral formulations might suit individual biology better. Patients ineligible for traditional GLP-1 therapy sometimes qualify for the Microdose GLP-1 Protocol ($129/month), which uses lower initial doses to minimize gastrointestinal or systemic risks while still delivering weight management benefits.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
Can I take semaglutide if I have type 2 diabetes and take insulin?
Insulin users can take semaglutide, but require dose adjustments to insulin and close blood sugar monitoring, as semaglutide significantly lowers glucose. PlexusDx screens all patients on insulin before dispensing and recommends coordinating with your primary care provider or endocrinologist throughout treatment.
Is semaglutide safe if my family has a history of thyroid cancer?
Family history of medullary thyroid carcinoma is a contraindication; personal history is absolute. If a close relative had thyroid cancer, PlexusDx requires genetic counseling confirmation that you do not carry MTC-linked mutations before proceeding with any GLP-1 medication.
What if I am pregnant or planning to get pregnant soon?
Semaglutide must be discontinued at least 2-3 months before conception due to drug persistence in your system. Women of childbearing age should confirm contraceptive plans with their provider before starting therapy through PlexusDx.
Does PlexusDx work with people who have pancreatitis history?
Patients with prior acute pancreatitis can sometimes use semaglutide under close monitoring, though chronic pancreatitis warrants specialist evaluation first. PlexusDx screens for pancreatitis history and coordinates with gastroenterologists to determine individual safety and appropriate dosing.
How does the Precision Peptide Genetic Test help if I have contraindications?
The Precision Peptide test identifies genetic variants in GLP1R, GIPR, FTO, and MC4R pathways to reveal which weight-management peptide mechanisms your body responds to best. For patients with relative contraindications to semaglutide, this test may show that tirzepatide or microdose protocols offer safer, more personalized alternatives.
Related Reading
Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
Is Wegovy for Weight Loss or Diabetes? Exploring Its Dual Purpose
Why Do People Use Ozempic for Weight Loss?